Trilaciclib (hydrochloride)

Trilaciclib (G1T28) hydrochloride is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy[1].

Product Specifications

CAS Number

[1977495-97-8]

Product Name Alternative

G1T28 (hydrochloride)

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Trilaciclib_hydrochloride.html

Purity

99.69

Solubility

H2O : 0.96 mg/mL (ultrasonic; adjust pH to 1 with 1 M HCL)

Smiles

O=C1C2=CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=N4)N=C3N2C6(CCCCC6)CN1.[H]Cl.[H]Cl

Molecular Formula

C24H32Cl2N8O

Molecular Weight

519.47

References & Citations

[1]Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15 (5) :783-93.